

### **DRL closes acquisition of Habitrol brand**

**HYDERABAD:** Dr. Reddy's Laboratories (DRL) has closed the acquisition of Habitrol brand from Novartis Consumer Health Inc. Habitrol is an over-the-counter nicotine replacement therapy transdermal patch. The acquisition was completed following the U.S. Federal Trade Commission issuing the consent order, a company release said. DRL had earlier entered into an asset purchase agreement with Novartis to acquire the title and rights of Habitrol brand and to market the product in the U.S. market. — Special Correspondent